Clinical trials: Pharynx Carcinoma
Nasopharyngeal Carcinoma
A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
This is a study to evaluate the efficacy and safety of TQB2450 injection combination with Intensity-modulated Radiotherapy in patients with inoperable locally recurrent nasopharyngeal carcinoma.
- Trial name
- NCT04895345
- Testing
- TQB2450, Intensity modulated radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nasopharyngeal Neoplasms, Herpesvirus 4, Human
Environmental and Genetic Determinants of NPC
Background: Nasopharyngeal carcinoma (NPC) a common malignant tumor in southern China and Southeast Asia. Infection with Epstein-Barr virus is believed to be necessary for the development of NPC; non-viral environmental factors…
- Trial name
- NCT01257100
- Where
- 6 sites in Taiwan
- Volunteers
- 3,500 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
The goal of this clinical trial is to compare the survival and adverse reactions differences between endoscopic surgery and intensity modulated radiotherapy for patients with newly diagnosed stage Ⅰ nasopharyngeal carcinoma…
- Conditions
- Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy, Surgery
- Trial name
- NCT06533267
- Testing
- Endoscopic nasopharyngectomy followed close follow-up, Intensity-modulated Radiotherapy
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma is the most common malignant tumor of head and neck in southern China. After standard treatment, about 20% of the patients had local recurrence or distant metastasis, and the patients faced death in a…
- Trial name
- NCT04917770
- Testing
- Sintilimab in combination with Multimodality Radiotherapy
- Volunteers
- 28 people
- Sponsor
- West China Hospital
Nasopharyngeal Carcinoma (NPC)
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07064902
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Human Papillomavirus-Related Carcinoma, Oropharyngeal Cancer
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
This is a single arm Phase I study of de-intensified hypofractionated radiation therapy for favorable human papilloma virus-associated oropharynx cancer.
- Trial name
- NCT04580446
- Testing
- Hypofractionated intensity modulated radiotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Head and Neck Cancer, Mucositis Oral
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy.
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Trial name
- NCT00293462
- Testing
- sargramostim, oral salt and soda mouthwash
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Marilyn Dodd
Oropharyngeal Cancer
Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer
The goal of this randomized treatment de-escalation study is to formally compare outcomes in HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary surgical approach, to provide a high level…
- Trial name
- ORATOR2 (NCT03210103)
- Testing
- Radiation, Transoral Surgery (TOS) + Neck Dissection
- Where
- 9 sites in Australia, Canada
- Volunteers
- 61 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Oropharynx Cancer
Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma
Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce toxicity.
- Trial name
- DeEscO (NCT06563362)
- Testing
- De-escalation of irradiated volume
- Where
- 7 sites in Switzerland
- Volunteers
- 120 people
- Sponsor
- University of Zurich
Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
- Trial name
- NCT04586088
- Testing
- Apatinib plus Camrelizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT06589804
- Testing
- Biospecimen Collection, Cetuximab, Computed Tomography
- Where
- 202 sites in United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Oropharyngeal Neoplasms
Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery
This trial examines the analgesia of the fibula free flap donor site by peri-neuronal catheter in oro-pharyngeal carcinoma surgery by comparing continuous infusion of a local anesthetic with systemic multimodal analgesia.
- Trial name
- NCT00181038
- Testing
- Peri-Neuronal Catheter
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Oropharyngeal Cancers, Biomarker in Early Diagnosis
Active MMP-8 in Oral Fluid for the Detection of Oral and Oropharyngeal Cancer
The goal of this observational study is to evaluate whether the active-matrix metalloproteinase-8 (aMMP-8) mouth-rinse test can help detect oral and oropharyngeal cancers.
- Conditions
- Oropharyngeal Cancers, Biomarker in Early Diagnosis, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Periodontal Diseases
- Trial name
- NCT06701058
- Where
- Finland
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Nasopharyngeal Carcinoma (NPC)
Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
This study aims to explore the efficacy and safety of scipibaimab combined with tislelizumab in patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after first-line therapy.
- Trial name
- NCT07388758
- Testing
- Tislelizumab, Scipibaimab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancer, Chemotherapy
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to chemo-radiotherapy could further decrease the rate of disease progression and improve the…
- Conditions
- Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
- Trial name
- NCT04453826
- Testing
- Camrelizumab plus chemo-radiotherapy, Chemo-radiotherapy alone
- Where
- 6 sites in China
- Volunteers
- 388 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of Oropharynx
Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention
Prospective pilot study, non-interventional, of a biological/radiological nature, which involves the collection of tissue samples, and blood from patients suffering from squamous cell carcinoma of the oropharynx OPSCC for…
- Trial name
- NCT06821243
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Regina Elena Cancer Institute
Nasopharyngeal Neoplasms, PD-1 Inhibitor
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined…
- Conditions
- Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
- Trial name
- NCT06811844
- Testing
- Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy
- Where
- 3 sites in China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Nasopharyngeal Carcinoma
Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NCT06248840
- Testing
- Intermittent Oral-esophageal Tube Feeding, nasogastric tube feeding
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zeng Changhao
Head and Neck Cancer
Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat
RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck.
- Trial name
- NCT00012168
- Testing
- isosulfan blue, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.